KCM Investment Advisors LLC Sells 125 Shares of Stryker Co. (NYSE:SYK)

KCM Investment Advisors LLC trimmed its holdings in Stryker Co. (NYSE:SYK) by 6.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,782 shares of the medical technology company’s stock after selling 125 shares during the quarter. KCM Investment Advisors LLC’s holdings in Stryker were worth $644,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Bank of Marin raised its holdings in shares of Stryker by 3.4% during the 3rd quarter. Bank of Marin now owns 2,301 shares of the medical technology company’s stock worth $831,000 after acquiring an additional 75 shares in the last quarter. Empowered Funds LLC raised its holdings in shares of Stryker by 6.5% during the 3rd quarter. Empowered Funds LLC now owns 6,504 shares of the medical technology company’s stock worth $2,350,000 after acquiring an additional 399 shares in the last quarter. Empirical Finance LLC raised its holdings in shares of Stryker by 2.4% during the 3rd quarter. Empirical Finance LLC now owns 11,556 shares of the medical technology company’s stock worth $4,175,000 after acquiring an additional 269 shares in the last quarter. Signature Estate & Investment Advisors LLC raised its holdings in shares of Stryker by 3.9% during the 3rd quarter. Signature Estate & Investment Advisors LLC now owns 1,459 shares of the medical technology company’s stock worth $527,000 after acquiring an additional 55 shares in the last quarter. Finally, Vectors Research Management LLC raised its holdings in Stryker by 2.4% during the 3rd quarter. Vectors Research Management LLC now owns 2,823 shares of the medical technology company’s stock valued at $1,020,000 after buying an additional 67 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Wolfe Research assumed coverage on Stryker in a report on Tuesday, September 10th. They set an “outperform” rating and a $405.00 price target on the stock. Truist Financial increased their price target on Stryker from $370.00 to $380.00 and gave the company a “hold” rating in a report on Wednesday, October 30th. Royal Bank of Canada increased their price target on Stryker from $386.00 to $400.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Canaccord Genuity Group increased their price target on Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Finally, Piper Sandler restated an “overweight” rating and set a $420.00 price target (up previously from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $393.65.

Insider Transactions at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP M Kathryn Fink sold 7,347 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total value of $2,696,202.06. Following the sale, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. This represents a 42.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 67,381 shares of company stock valued at $24,825,275. 5.90% of the stock is currently owned by corporate insiders.

Stryker Price Performance

SYK stock opened at $390.08 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $148.71 billion, a PE ratio of 41.81, a P/E/G ratio of 2.89 and a beta of 0.91. Stryker Co. has a 12-month low of $282.35 and a 12-month high of $392.70. The business’s fifty day moving average price is $364.07 and its 200 day moving average price is $347.33.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. During the same quarter in the previous year, the business earned $2.46 EPS. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Stryker Co. will post 12.06 EPS for the current year.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.